Upstream Processing

Oct 01, 2007
BioPharm International
Multivariate data analysis can help biotech manufacturers deepen their process understanding.
Oct 01, 2007
BioPharm International
In one series of experiments, the glycosylation site of IgG1 was removed and an IgA glycosylation site was introduced—resulting in a total loss of biological function.
Oct 01, 2007
BioPharm International
By BioPharm International Editors
It became a strategic imperative to find a better, more efficient way to manufacture our products. To continue with the status quo was untenable.
Oct 01, 2007
BioPharm International
By BioPharm International Editors
It is commonly believed that technologies in the next 10–15 years will enable sequencing an individualized human genome for less than $1,000. With innovations like these, the twenty-first century will certainly belong to biotechnology. From an industrial standpoint, the discovery of therapeutic molecules and the development of cell lines and processes to produce these molecules will be of paramount importance. This article describes various approaches that have been prevalent in the industry or are likely to be used in the future for generating cell lines with desirable traits and developing high titer cell culture processes.
Oct 01, 2007
BioPharm International
By BioPharm International Editors
Favrille, a San Diego-based biopharmaceutical company, is one of a handful of firms on the forefront of personalized medicine. Because personalized treatment is tailored to an individual's biology, it has the potential to be far more effective than current approaches to disease management.
Oct 01, 2007
BioPharm International
Regulatory agencies have evolved along with the biotechnology industry to define quality standards.
Sep 01, 2007
BioPharm International
By BioPharm International Editors
From the earliest days of the biotechnology industry, companies have grappled with the complexities of making innovative biopharmaceuticals on a large scale. Success in manufacturing begins with process science, since biotech production requires perfection in maintaining living organisms in a sterile environment under controlled physiological conditions. But unless companies can solve the challenge of planning for and managing manufacturing capacity, they will not be able to achieve the full potential of promising biotech products.
Sep 01, 2007
BioPharm International
There were notable approvals in nonparenteral delivery systems and biosimiliars in 2006.
Sep 01, 2007
BioPharm International
In analyzing the industry's current challenges, let's be careful before extrapolating about what they mean.
Aug 21, 2007
BioPharm International
By BioPharm International Editors
SemBioSys Genetics, Inc. (Calgary, Canada, www.sembiosys.com) announced that it has successfully produced commercial levels of apolipoprotein AI and its variant apolipoprotein AI(Milano), collectively referred to as Apo AI, in safflower seed lines.
native1_300x100
lorem ipsum